Skin protectant drug products for over-the-counter human use; astringent drug products; final monograph; direct final rule. Direct final rule.
The Food and Drug Administration (FDA) is amending the regulation that established conditions under which over-the-counter (OTC) skin protectant astringent drug products are generally recognized as safe and effective and not misbranded. This action revises some labeling for astringent drug products to be consistent with the final rule for OTC skin protectant drug products (68 FR 33362, June 4, 2003) and adds labeling for certain small packages (styptic pencils). This action is part of FDA's ongoing review of OTC drug products. Elsewhere in this issue of the Federal Register, FDA is publishing a companion proposed rule, under FDA's usual procedure for notice-and-comment rulemaking, to provide a procedural framework to finalize the rule in the event the agency receives any significant adverse comments and withdraws this direct final rule.
D017607:Aluminum Compounds / Q000145:classification; D001252:Astringents / Q000145:classification*; D018554:Avena / Q000145:classification; D003102:Colloids / Q000145:classification; D003257:Consumer Product Safety / Q000331:legislation & jurisprudence*; D017277:Drug Approval / Q000331:legislation & jurisprudence; D004348:Drug Labeling / Q000331:legislation & jurisprudence*; D006801:Humans; D004366:Nonprescription Drugs / Q000145:classification*; D020011:Protective Agents / Q000145:classification*; D017693:Sodium Bicarbonate / Q000145:classification; D014481:United States; D014486:United States Food and Drug Administration
D017607:Aluminum Compounds; D001252:Astringents; D003102:Colloids; D004366:Nonprescription Drugs; D020011:Protective Agents; D017693:Sodium Bicarbonate